Cationic Lipids Offer New Possibilities in Liposome and LNP Engineering for RNA Therapeutics
Jean-Thomas Issenhuth,
Key Account Manager EMEA,
Polyplus-Transfection
Lipid-based nanoparticles (LNPs) represent one of the most promising RNA
delivery systems, not only due to their efficacy, but also to the ease
of production achieved through precise controlled mixing technique known
as microfluidics and the scalability of production. Still, they present
some limitations related to toxicity, targeting, limited
biodistribution through systemic administration which mainly results in
liver uptake. Polyplus® has recently developed a library of cationic lipids (LipidBrick®),
which represents a remarkable innovation compared with conventional
cationic lipids by ensuring reduced toxicity of LNPs and extending their
use beyond the liver.
|
|
